Business
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Data validates continued high radiation absorbed of 186RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"Data validates continued high radiation absorbed of 186RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure Company will also present at upcoming BIO International Convention 2022 being held June 13-16 in San Diego, California AUSTIN, Texas, June 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present positive data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the Phase 1/2a ReSPECT™-GBM dose escalation clinical trial in patients with recurrent glioblastoma (GBM) during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, on June 14 at 10:20 AM PT in Vancouver, British Columbia, Canada. According to the interim data, 186RNL delivered via convection enhanced delivery (CED) provides direct therapy with high radiation absorbed doses for local tumor control with minimal brain and whole-body radiation exposure. 186RNL’s tumor-killing effects were observed when greater than 100 Gy doses are delivered to greater than 80% of a tumor without dose-limiting toxicity. The presentation, titled “Rhenium-186-NanoLiposome (186RNL) in the treatment of relapse/recurrent glioblastoma (rGBM): a novel approach to cancer therapy,” outlines data from the ReSPECT-GBM trial, substantially funded by the U.S. National Institutes of Health/National Cancer Institute, which has thus far evaluated 24 adult patients with recurrent GBM across seven cohorts of increasing dose. To date, there have been no significant adverse events during the dose escalation. “186RNL’s novel localized radio-nanotherapeutic approach has significant potential to translate into treatment for a broad range of tumors where local tumor control is difficult or all other therapies are exhausted, ineffective or toxic,” said William Phillips, M.D., Nuclear Medicine Physician at UT Health-San Antonio, and primary presenter. “To treat glioblastoma, the targeted and controlled use of 186RNL is critical for patients as we aim to mitigate brain and whole-body exposure. The novel administration via localized radio-nanotherapeutic enables high doses of radiation to be abso...